N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals

“

TL;DR

N-acetylcysteine (NAC) is a safe, inexpensive antioxidant and immunomodulatory agent with therapeutic potential for a wide range of conditions involving oxidative stress, including liver diseases, pulmonary disorders, infectious diseases, and animal health issues such as weaning disorders and mastitis. Its clinical significance lies in its ability to replenish glutathione, scavenge free radicals, and modulate inflammation, though its mechanisms of action remain incompletely understood and may involve hydrogen sulfide/sulfane sulfur pathways. Further research is needed to establish optimal dosing, routes of administration, and treatment protocols for each condition.

Full summary

5,470 CHARS

**Background:** N-acetylcysteine (NAC) is an FDA-approved drug (since 1963) for acetaminophen overdose and a mucolytic agent, also sold as an over-the-counter supplement. Its antioxidant, anti-inflammatory, and cytoprotective properties make it a promising therapeutic for conditions where oxidative stress plays a key role, including diabetes, obesity, cardiovascular, neurodegenerative, respiratory, and infectious diseases in humans, as well as weaning disorders, respiratory disease, diarrhea, endometritis, and mastitis in domesticated animals. Despite numerous studies, the mechanisms of action (MOA) remain unclear, with three major narratives (direct radical scavenging, glutathione replenishment, disulfide reduction) and an emerging alternative via hydrogen sulfide/sulfane sulfur species.

**Methods:** This is a narrative review of the literature on NAC's therapeutic uses in humans and domesticated animals, its safety profile, pharmacokinetics, and proposed mechanisms of action. The authors synthesized findings from clinical trials, animal studies, and in vitro experiments, covering a range of conditions and species.

**Key Results:** - **Pharmacokinetics:** NAC has low oral bioavailability (<10%) due to first-pass metabolism. In humans, half-life is 5.58 h (IV) and 6.25 h (oral), with Cmax at 1–2 h. Oral doses of 600–1200 mg/day are common, and up to 8000 mg/day are well-tolerated. In cats, half-life is 0.78 ± 0.16 h (IV) and 1.34 ± 0.24 h (oral), bioavailability 19.3 ± 4.4%. In broilers, Cmax 2.26 ± 0.91 g/mL at 2.47 ± 0.45 h, half-life 1.04 ± 0.53 h. - **Safety:** Adverse effects are mild and dose-dependent; nausea, vomiting, pruritus, erythema are common. Anaphylactoid reactions are rare, mostly with IV administration. - **Human Studies:** - **Acetaminophen overdose:** NAC within 8 h prevents hepatotoxicity; oral and IV are equally effective within 10 h. - **Non-alcoholic fatty liver disease (NAFLD):** 600 mg NAC twice daily for 3 months decreased serum ALT compared to vitamin C. - **Chronic obstructive pulmonary disease (COPD):** 600 mg/day NAC for 12 months reduced H2O2 in expired breath condensate by 2.3-fold at 9 months and 2.6-fold at 12 months vs placebo. - **Cystic fibrosis:** 2800 mg/day NAC for 12 weeks increased sputum GSH but did not alter clinical parameters. - **Influenza:** NAC (600 mg twice daily for 6 months) reduced clinically apparent H1N1 influenza in seniors and improved cell-mediated immunity. - **COVID-19:** In a case series, 600 mg IV NAC twice daily reduced CRP and ferritin, improved liver function, and reduced oxygen requirement; 9 of 10 patients discontinued ECMO. - **Ulcerative colitis:** 800 mg NAC for 16 weeks reduced endoscopic relapse, CRP, fecal calprotectin, and erythrocyte sedimentation rate vs placebo. - **Diabetes:** IV NAC during hyperglycemic clamp improved insulin sensitivity and peripheral glucose uptake. - **Animal Studies:** - **Swine weaning:** 500 mg/kg dietary NAC improved intestinal morphology, reduced LPS-induced oxidative stress (increased SOD, CAT, GSH-Px; decreased MDA, H2O2, O2•−), and altered gut microbiota (increased Lactobacillus and Bifidobacterium, decreased E. coli). - **Porcine epidemic diarrhea (PED):** NAC supplementation alleviated intestinal injury, improved villus height and absorptive function, and reduced plasma H2O2. - **Bovine endometritis:** NAC treatment resulted in 77.2% clinical cure rate vs 43.4% in controls, and pregnancy rate 66.7% vs 54.6%. - **Bovine mastitis:** 10 mM NAC reduced MICs of penicillin and ampicillin against S. aureus, S. dysgalactiae, E. coli, and S. agalactiae. - **Poultry:** 800 mg/kg NAC per day mitigated aflatoxin B1 toxicity; 0.1% NAC mitigated cold-induced oxidative stress; 1 g/kg NAC improved growth performance in heat-stressed broilers. - **Canine parvovirus:** NAC treatment improved leukocyte counts, increased GST activity, and decreased nitric oxide and MDA on days 3 and 5 vs supportive therapy alone. - **Infectious keratitis in dogs and cats:** NAC had in vitro antimicrobial activity against all tested isolates (MIC 0.156–0.625%, 1.56–6.25 mg/mL), including methicillin-resistant S. pseudintermedius. - **Canine otitis externa:** NAC inhibited all isolates (MIC 5–20 mg/mL) and disrupted biofilms. - **Mechanisms:** NAC's direct antioxidant activity is limited by slow reaction rates with key oxidants (e.g., k for H2O2 = 0.16 M−1 s−1 vs GSH 0.89). Its main effects are attributed to GSH replenishment (via deacetylation to cysteine) and disulfide reduction (mucolytic). An alternative MOA involves conversion to H2S and sulfane sulfur species, which have cytoprotective properties independent of GSH synthesis.

**Clinical Implications:** NAC is a well-tolerated, inexpensive adjunct therapy for conditions with oxidative stress and inflammation. In humans, it is established for acetaminophen overdose and shows promise for COPD, cystic fibrosis, influenza, COVID-19, NAFLD, and IBD. In veterinary medicine, it improves outcomes in weaning disorders, mastitis, endometritis, parvovirus, and infectious keratitis. However, its efficacy is context-dependent, and optimal dosing, route, and duration need to be defined for each indication. The emerging H2S/sulfane sulfur pathway may explain GSH-independent effects and opens new therapeutic avenues. Clinicians should consider NAC as an immunoceutical, especially when oxidative stress is a major contributor.